Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Algorithmic Versus Expert Human Interpretation of Instantaneous Wave-Free Ratio Coronary Pressure-Wire Pull Back Data.

Cook CM, Warisawa T, Howard JP, Keeble TR, Iglesias JF, Schampaert E, Bhindi R, Ambrosia A, Matsuo H, Nishina H, Kikuta Y, Shiono Y, Nakayama M, Doi S, Takai M, Goto S, Yakuta Y, Karube K, Akashi YJ, Clesham GJ, Kelly PA, Davies JR, Karamasis GV, Kawase Y, Robinson NM, Sharp ASP, Escaned J, Davies JE.

JACC Cardiovasc Interv. 2019 Jul 22;12(14):1315-1324. doi: 10.1016/j.jcin.2019.05.025.

2.

Bypass Surgery or Stenting for Left Main Coronary Artery Disease in Patients With Diabetes.

Milojevic M, Serruys PW, Sabik JF 3rd, Kandzari DE, Schampaert E, van Boven AJ, Horkay F, Ungi I, Mansour S, Banning AP, Taggart DP, Sabaté M, Gershlick AH, Bochenek A, Pomar J, Lembo NJ, Noiseux N, Puskas JD, Crowley A, Kosmidou I, Mehran R, Ben-Yehuda O, Généreux P, Pocock SJ, Simonton CA, Stone GW, Kappetein AP.

J Am Coll Cardiol. 2019 Apr 9;73(13):1616-1628. doi: 10.1016/j.jacc.2019.01.037.

PMID:
30947913
3.

Ten-Year Statin Adherence in Survivors of ST-Segment Elevation Myocardial Infarction.

Huynh T, Lecca P, Montigny M, Gagnon R, Eisenberg MJ, Lauzon C, Mansour S, Rinfret S, Afilalo M, Nguyen M, Kouz S, Dery JP, Harvey R, Schampaert E, Tardif JC.

J Popul Ther Clin Pharmacol. 2018 Nov 6;25(2):e63-e77. doi: 10.22374/1710-6222.25.2.5.

PMID:
30725543
4.

Impact of an invasive strategy in the elderly hospitalized with acute coronary syndrome with emphasis on the nonagenarians.

Couture EL, Farand P, Nguyen M, Allard C, Wells GA, Mansour S, Rinfret S, Afilalo J, Eisenberg M, Montigny M, Kouz S, Afilalo M, Lauzon C, Dery JP, L'Allier P, Schampaert E, Tardif JC, Huynh T.

Catheter Cardiovasc Interv. 2018 Dec 1;92(7):E441-E448. doi: 10.1002/ccd.27877. Epub 2018 Sep 30.

PMID:
30269415
5.

Recurrent Cardiovascular Events in Survivors of Myocardial Infarction With ST-Segment Elevation (from the AMI-QUEBEC Study).

Huynh T, Montigny M, Iftikhar U, Gagnon R, Eisenberg M, Lauzon C, Mansour S, Rinfret S, Afilalo M, Nguyen M, Kouz S, Déry JP, Harvey R, De LaRocheliere R, Cantin B, Schampaert E, Tardif JC.

Am J Cardiol. 2018 Apr 15;121(8):897-902. doi: 10.1016/j.amjcard.2017.12.037. Epub 2018 Jan 31.

PMID:
29452691
6.

New-Onset Atrial Fibrillation After PCI or CABG for Left Main Disease: The EXCEL Trial.

Kosmidou I, Chen S, Kappetein AP, Serruys PW, Gersh BJ, Puskas JD, Kandzari DE, Taggart DP, Morice MC, Buszman PE, Bochenek A, Schampaert E, Pagé P, Sabik JF 3rd, McAndrew T, Redfors B, Ben-Yehuda O, Stone GW.

J Am Coll Cardiol. 2018 Feb 20;71(7):739-748. doi: 10.1016/j.jacc.2017.12.012.

7.

Ultrasound guidance versus anatomical landmark approach for femoral artery access in coronary angiography: A randomized controlled trial and a meta-analysis.

Marquis-Gravel G, Tremblay-Gravel M, Lévesque J, Généreux P, Schampaert E, Palisaitis D, Doucet M, Charron T, Terriault P, Tessier P.

J Interv Cardiol. 2018 Aug;31(4):496-503. doi: 10.1111/joic.12492. Epub 2018 Jan 25.

PMID:
29372578
8.

Potential Sunitinib-Induced Coronary Artery and Aortic Dissections.

Hatem R, Bebawi E, Schampaert E.

Can J Cardiol. 2017 Jun;33(6):830.e17-830.e18. doi: 10.1016/j.cjca.2017.03.002. Epub 2017 Mar 9.

PMID:
28461000
9.

Longitudinal treatment patterns with ADP receptor inhibitors after myocardial infarction: Insights from the Canadian Observational AntiPlatelet sTudy.

Bagai A, Wang TY, Goodman SG, Fisher HN, Welsh RC, Dery JP, Zhang X, Zhu YE, Cheema AN, Dehghani P, Kassam SA, Ducas J, Brass N, Kim HH, Fung A, Schampaert E, Quraishi AU, Mehta SR; Canadian Observational AntiPlatelet sTudy (COAPT) Investigators.

Int J Cardiol. 2017 Feb 1;228:459-464. doi: 10.1016/j.ijcard.2016.11.240. Epub 2016 Nov 14.

PMID:
27870977
10.

Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease.

Stone GW, Sabik JF, Serruys PW, Simonton CA, Généreux P, Puskas J, Kandzari DE, Morice MC, Lembo N, Brown WM 3rd, Taggart DP, Banning A, Merkely B, Horkay F, Boonstra PW, van Boven AJ, Ungi I, Bogáts G, Mansour S, Noiseux N, Sabaté M, Pomar J, Hickey M, Gershlick A, Buszman P, Bochenek A, Schampaert E, Pagé P, Dressler O, Kosmidou I, Mehran R, Pocock SJ, Kappetein AP; EXCEL Trial Investigators.

N Engl J Med. 2016 Dec 8;375(23):2223-2235. Epub 2016 Oct 31.

11.

Can We Just Rely on Contrast?

Schampaert E, Mansour S, Palisaitis DA.

Can J Cardiol. 2016 Jun;32(6):717-9. doi: 10.1016/j.cjca.2015.10.006. Epub 2015 Oct 22. No abstract available.

PMID:
26907168
12.

Brain Natriuretic Peptide Levels and the Occurrence of Subclinical Pulmonary Edema in Healthy Lowlanders at High Altitude.

Pagé M, Henri C, Pagé P, Sauvé C, Schampaert E.

Can J Cardiol. 2015 Aug;31(8):1025-31. doi: 10.1016/j.cjca.2015.03.024. Epub 2015 Mar 27.

PMID:
26118450
13.

Excellent outcomes for transcatheter aortic valve replacement within 1 year of opening a low-volume centre and consideration of requirements.

Chevalier F, Poulin F, Lamarche Y, Viet Le VH, Gallant M, Daoust A, Heylbroeck C, Serri K, Beaulieu Y, Demers P, El-Hamamsy I, Jeanmart H, Pagé P, Schampaert E, Palisaitis D, Généreux P.

Can J Cardiol. 2014 Dec;30(12):1576-82. doi: 10.1016/j.cjca.2014.08.010. Epub 2014 Aug 22.

PMID:
25442458
14.

Evidence of platelet sensitization to ADP following discontinuation of clopidogrel therapy in patients with stable coronary artery disease.

Lordkipanidzé M, Diodati JG, Schampaert E, Palisaitis DA, Pharand C.

Platelets. 2015;26(6):545-51. doi: 10.3109/09537104.2014.951318. Epub 2014 Aug 28.

PMID:
25167467
15.

Bioresorbable vascular scaffold use in a case of in-stent restenosis.

Cadrin-Tourigny J, Dong L, Maehara A, Schampaert E, Genereux P.

Arq Bras Cardiol. 2014 Jul;103(1):e11-4. English, Portuguese. No abstract available.

16.

Echocardiographic assessment of cardiac performance in response to high altitude and development of subclinical pulmonary edema in healthy climbers.

Pagé M, Sauvé C, Serri K, Pagé P, Yin Y, Schampaert E.

Can J Cardiol. 2013 Oct;29(10):1277-84. doi: 10.1016/j.cjca.2013.04.025. Epub 2013 Jul 17.

PMID:
23871437
17.

Canada Acute Coronary Syndrome Risk Score: a new risk score for early prognostication in acute coronary syndromes.

Huynh T, Kouz S, Yan AT, Danchin N, O'Loughlin J, Schampaert E, Yan RT, Rinfret S, Tardif JC, Eisenberg MJ, Afilalo M, Chong A, Dery JP, Nguyen M, Lauzon C, Mansour S, Ko DT, Tu JV, Goodman S.

Am Heart J. 2013 Jul;166(1):58-63. doi: 10.1016/j.ahj.2013.03.023. Epub 2013 Apr 30. Erratum in: Am Heart J. 2013 Sep;166(3):604. Yan, Andrew [corrected to Yan, Andrew T]; Loughlin, Jennifer O [corrected to O'Loughlin, Jennifer]; Yan, Raymond [corrected to Yan, Raymond T].

PMID:
23816022
18.

Porcine model of intracoronary pulverization of stent struts by rotablation atherectomy.

Quang TT, Hatem R, Rousseau G, Dube B, Samson C, Schampaert E, Charron T.

Catheter Cardiovasc Interv. 2013 Dec 1;82(7):E842-8. doi: 10.1002/ccd.24650. Epub 2013 Sep 2.

PMID:
22945809
19.

2010 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiologists Guidelines for Training and Maintenance of Competency in Adult Interventional Cardiology.

Palisaitis D, Love M, Zimmerman R, Radhakrishnan S, Welsh R, Saw J, Renner S, Kells C, Schampaert E.

Can J Cardiol. 2011 Nov-Dec;27(6):865-7. doi: 10.1016/j.cjca.2011.06.009. Epub 2011 Sep 14.

PMID:
21920696
20.

Genetic determinants of response to aspirin: appraisal of 4 candidate genes.

Lordkipanidzé M, Diodati JG, Palisaitis DA, Schampaert E, Turgeon J, Pharand C.

Thromb Res. 2011 Jul;128(1):47-53. doi: 10.1016/j.thromres.2011.02.019. Epub 2011 Mar 22.

PMID:
21429568
21.

Comparison of electrocardiographic recordings in open-chest and closed-chest swine models.

Shousha S, Diodati JG, de Chantal M, Charron T, Amyot R, Schampaert E, Pharand C.

J Am Assoc Lab Anim Sci. 2010 Nov;49(6):852-5.

22.

Impact of moderate renal insufficiency on restenosis and adverse clinical events after sirolimus-eluting and bare metal stent implantation (from the SIRIUS trials).

Garg P, Charytan DM, Novack L, Cutlip DE, Popma JJ, Moses J, Leon MB, Schofer J, Breithardt G, Schampaert E, Mauri L.

Am J Cardiol. 2010 Nov 15;106(10):1436-42. doi: 10.1016/j.amjcard.2010.07.011.

PMID:
21059433
23.

Effectiveness and safety of glycoprotein IIb/IIIa inhibitors in patients with myocardial infarction undergoing primary percutaneous coronary intervention: a meta-analysis of observational studies.

Kouz R, Kouz S, Schampaert E, Rinfret S, Tardif JC, Nguyen M, Eisenberg M, Harvey R, Afilalo M, Lauzon C, Dery JP, Mansour S, Huynh T.

Int J Cardiol. 2011 Dec 15;153(3):249-55. doi: 10.1016/j.ijcard.2010.08.019. Epub 2010 Oct 25.

PMID:
20971515
24.

Safety and effectiveness of enoxaparin following fibrinolytic therapy: Results of the Acute Myocardial Infarction (AMI)-QUEBEC registry.

El-Rayes M, Schampaert E, Tardif JC, Eisenberg MJ, Afilalo M, Kouz S, Lauzon C, Harvey R, Nguyen M, Kouz R, Dery JP, Mansour S, Van Kieu AM, Rinfret S, Huynh T.

Can J Cardiol. 2010 Oct;26(8):431-6.

25.

Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease.

Lordkipanidzé M, Pharand C, Schampaert E, Palisaitis DA, Diodati JG.

Int J Cardiol. 2011 Jul 1;150(1):39-44. doi: 10.1016/j.ijcard.2010.02.025. Epub 2010 Mar 7.

PMID:
20207433
26.

Prevalence of unresponsiveness to aspirin and/or clopidogrel in patients with stable coronary heart disease.

Lordkipanidzé M, Diodati JG, Schampaert E, Palisaitis DA, Pharand C.

Am J Cardiol. 2009 Nov 1;104(9):1189-93. doi: 10.1016/j.amjcard.2009.06.025. Epub 2009 Sep 16.

PMID:
19840560
27.

5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.

Caixeta A, Leon MB, Lansky AJ, Nikolsky E, Aoki J, Moses JW, Schofer J, Morice MC, Schampaert E, Kirtane AJ, Popma JJ, Parise H, Fahy M, Mehran R.

J Am Coll Cardiol. 2009 Sep 1;54(10):894-902. doi: 10.1016/j.jacc.2009.04.077.

28.

Week-long high-maintenance dose clopidogrel regimen achieves better platelet aggregation inhibition than a standard loading dose before percutaneous coronary intervention: results of a double-blind, randomized clinical trial.

Nguyen TA, Lordkipanidzé M, Diodati JG, Palisaitis DA, Schampaert E, Turgeon J, Pharand C.

J Interv Cardiol. 2009 Aug;22(4):368-77. doi: 10.1111/j.1540-8183.2009.00486.x.

PMID:
19689661
29.

Insights into the interpretation of light transmission aggregometry for evaluation of platelet aggregation inhibition by clopidogrel.

Lordkipanidzé M, Pharand C, Palisaitis DA, Schampaert E, Diodati JG.

Thromb Res. 2009 Nov;124(5):546-53. doi: 10.1016/j.thromres.2009.04.003. Epub 2009 May 5.

PMID:
19419755
30.

Evaluation of the platelet count drop method for assessment of platelet function in comparison with "gold standard" light transmission aggregometry.

Lordkipanidzé M, Pharand C, Schampaert E, Palisaitis DA, Diodati JG.

Thromb Res. 2009 Sep;124(4):418-22. doi: 10.1016/j.thromres.2009.02.002. Epub 2009 Feb 28.

PMID:
19250657
31.

Platelet count, not oxidative stress, may contribute to inadequate platelet inhibition by aspirin.

Lordkipanidzé M, Diodati JG, Turgeon J, Schampaert E, Palisaitis DA, Pharand C.

Int J Cardiol. 2010 Aug 6;143(1):43-50. doi: 10.1016/j.ijcard.2009.01.037. Epub 2009 Feb 11.

PMID:
19215991
32.

Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients.

Lordkipanidzé M, Pharand C, Nguyen TA, Schampaert E, Palisaitis DA, Diodati JG.

Eur Heart J. 2008 Dec;29(23):2877-85. doi: 10.1093/eurheartj/ehn419. Epub 2008 Sep 30.

PMID:
18826988
33.

Assessment of VerifyNow P2Y12 assay accuracy in evaluating clopidogrel-induced platelet inhibition.

Lordkipanidzé M, Pharand C, Nguyen TA, Schampaert E, Diodati JG.

Ther Drug Monit. 2008 Jun;30(3):372-8. doi: 10.1097/FTD.0b013e3181757c59.

PMID:
18520610
34.

Impact of platelet glycoprotein IIb/IIIa receptor inhibitors on outcomes of diabetic patients undergoing percutaneous coronary interventions using sirolimus-eluting stents.

Nikolsky E, Holmes DR, Mehran R, Dangas G, Schampaert E, Morice MC, Schofer J, Sousa JE, Fahy M, Na Y, Donohoe DJ, Moses JW, Leon MB.

Catheter Cardiovasc Interv. 2008 Jun 1;71(7):896-906. doi: 10.1002/ccd.21548.

PMID:
18498145
35.

Gender-specific outcomes after sirolimus-eluting stent implantation.

Solinas E, Nikolsky E, Lansky AJ, Kirtane AJ, Morice MC, Popma JJ, Schofer J, Schampaert E, Pucelikova T, Aoki J, Fahy M, Dangas GD, Moses JW, Cutlip DE, Leon MB, Mehran R.

J Am Coll Cardiol. 2007 Nov 27;50(22):2111-6. Epub 2007 Nov 13.

36.

A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease.

Lordkipanidzé M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG.

Eur Heart J. 2007 Jul;28(14):1702-8. Epub 2007 Jun 14.

PMID:
17569678
37.

Drug-eluting stents.

Rinfret S, Schampaert E.

CMAJ. 2007 May 22;176(11):1611-2. No abstract available.

38.

The Canadian Association of Interventional Cardiology and the Canadian Cardiovascular Society joint statement on drug-eluting stents.

Love MP, Schampaert E, Cohen EA, Webb JG, Anderson TJ, Labinaz M, Tanguay JF, Dzavík V; Canadian Association of Interventional Cardiology; Canadian Cardiovascular Society.

Can J Cardiol. 2007 Feb;23(2):121-3.

39.

Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.

Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB.

N Engl J Med. 2007 Mar 8;356(10):998-1008. Epub 2007 Feb 12.

40.

Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial.

Tardif JC, Grégoire J, L'Allier PL, Ibrahim R, Anderson TJ, Reeves F, Title LM, Schampaert E, LeMay M, Lespérance J, Scott R, Guertin MC, Brennan ML, Hazen SL, Bertrand OF; CART-2 Investigators.

Atherosclerosis. 2008 Mar;197(1):480-6. Epub 2007 Jan 9.

PMID:
17214993
41.

Delays to reperfusion therapy in acute ST-segment elevation myocardial infarction: results from the AMI-QUEBEC Study.

Huynh T, O'Loughlin J, Joseph L, Schampaert E, Rinfret S, Afilalo M, Kouz S, Cantin B, Nguyen M, Eisenberg MJ; AMI-QUEBEC Study Investigators.

CMAJ. 2006 Dec 5;175(12):1527-32.

42.

Cause of death with bare metal and sirolimus-eluting stents.

Holmes DR Jr, Moses JW, Schofer J, Morice MC, Schampaert E, Leon MB.

Eur Heart J. 2006 Dec;27(23):2815-22. Epub 2006 Nov 15.

PMID:
17107976
43.

Progressive epicardial coronary blood flow reduction fails to produce ST-segment depression at normal heart rates.

de Chantal M, Diodati JG, Nasmith JB, Amyot R, LeBlanc AR, Schampaert E, Pharand C.

Am J Physiol Heart Circ Physiol. 2006 Dec;291(6):H2889-96. Epub 2006 Aug 11.

44.

Periprocedural and late consequences of overlapping Cypher sirolimus-eluting stents: pooled analysis of five clinical trials.

Kereiakes DJ, Wang H, Popma JJ, Kuntz RE, Donohoe DJ, Schofer J, Schampaert E, Meier B, Leon MB, Moses JW.

J Am Coll Cardiol. 2006 Jul 4;48(1):21-31. Epub 2006 Jun 12.

45.

Sirolimus-eluting stents at two years: a pooled analysis of SIRIUS, E-SIRIUS, and C-SIRIUS with emphasis on late revascularizations and stent thromboses.

Schampaert E, Moses JW, Schofer J, Schlüter M, Gershlick AH, Cohen EA, Palisaitis DA, Breithardt G, Donohoe DJ, Wang H, Popma JJ, Kuntz RE, Leon MB; SIRIUS, E- and C-SIRIUS Investigators.

Am J Cardiol. 2006 Jul 1;98(1):36-41. Epub 2006 May 4.

PMID:
16784917
46.

Cost effectiveness of the sirolimus-eluting stent in high-risk patients in Canada: an analysis from the C-SIRIUS trial.

Rinfret S, Cohen DJ, Tahami Monfared AA, Lelorier J, Mireault J, Schampaert E.

Am J Cardiovasc Drugs. 2006;6(3):159-68.

PMID:
16780389
47.

Diagnostic specificity and prognostic value of cardiac troponins in asymptomatic chronic haemodialysis patients: a three year prospective study.

Troyanov S, Ly QH, Schampaert E, Ammann H, Lalumière G, Madore F, Quérin S.

Heart. 2005 Sep;91(9):1227-8. No abstract available.

48.

Sustained cardioprotection afforded by A2A adenosine receptor stimulation after 72 hours of myocardial reperfusion.

Boucher M, Wann BP, Kaloustian S, Massé R, Schampaert E, Cardinal R, Rousseau G.

J Cardiovasc Pharmacol. 2005 May;45(5):439-46.

PMID:
15821439
49.

Direct stenting of native de novo coronary artery lesions with the sirolimus-eluting stent: a post hoc subanalysis of the pooled E- and C-SIRIUS trials.

Schlüter M, Schofer J, Gershlick AH, Schampaert E, Wijns W, Breithardt G; E- and C-SIRIUS Investigators.

J Am Coll Cardiol. 2005 Jan 4;45(1):10-3.

50.

Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions.

Tardif JC, Grégoire J, L'Allier PL, Anderson TJ, Bertrand O, Reeves F, Title LM, Alfonso F, Schampaert E, Hassan A, McLain R, Pressler ML, Ibrahim R, Lespérance J, Blue J, Heinonen T, Rodés-Cabau J; Avasimibe and Progression of Lesions on UltraSound (A-PLUS) Investigators.

Circulation. 2004 Nov 23;110(21):3372-7. Epub 2004 Nov 8.

PMID:
15533865

Supplemental Content

Loading ...
Support Center